» Articles » PMID: 1017153

Clinical Pharmacokinetics in Infants and Children

Overview
Specialty Pharmacology
Date 1976 Jan 1
PMID 1017153
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Wide variations in drug dose recommendations for children of the same or different ages reflect the inadequacy of data on pharmacokinetics and pharmacodynamics in children. Selected aspects of available literature on pharmacokinetics of drugs used in older infants and children has been reviewed with special attention to calculation of an age-appropriate dose. During the neonatal period and early infancy the elimination of many drugs that are excreted in the urine in unchanged form is restricted by the immaturity of glomerular filtration and renal tubular secretion. On the other hand, in late infancy and/or in childhood, a similar or greater rate of elimination from plasma than in adults has been observed for many drugs, notably digoxin, phenobarbitone, phenytoin, carbamazepine, ethosuximide, diazoxide, clindamycin and propoxyphene. Consistent with this, it has been shown that some drugs exhibit a lower plasma level/dose ratio in infancy and early childhood as compared with the adult. This is true for phenobarbitone, phenytoin and ethosuximide. Some age groups of children remain uninvestigated with regard to pharmacokinetics, even for the drugs reviewed. Therefore, pediatric therapy remains empirically based for many drugs.

Citing Articles

Estimation of Pediatric Dosage of Antimalarial Drugs, Using Pharmacokinetic and Physiological Approach.

Mhango E, Snorradottir B, Kachingwe B, Katundu K, Gizurarson S Pharmaceutics. 2023; 15(4).

PMID: 37111562 PMC: 10140824. DOI: 10.3390/pharmaceutics15041076.


Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults.

Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos J Pharmaceutics. 2013; 3(1):53-72.

PMID: 24310425 PMC: 3857037. DOI: 10.3390/pharmaceutics3010053.


Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.

Wells T, Blowey D, Sullivan J, Blumer J, Sherbotie J, Song S Paediatr Drugs. 2012; 14(6):401-9.

PMID: 22880942 DOI: 10.2165/11631450-000000000-00000.


Ontogeny of drug elimination by the human kidney.

Chen N, Aleksa K, Woodland C, Rieder M, Koren G Pediatr Nephrol. 2005; 21(2):160-8.

PMID: 16331517 DOI: 10.1007/s00467-005-2105-4.


The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.

Leslie L, Newman T, Chesney P, Perrin J Pediatrics. 2005; 116(1):195-204.

PMID: 15995053 PMC: 1550709. DOI: 10.1542/peds.2005-0074.


References
1.
Eichelbaum M, Ekbom K, Bertilsson L, Ringberger V, Rane A . Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975; 8(5):337-41. DOI: 10.1007/BF00562659. View

2.
Wettrell G, Andersson K, BERTLER A, LUNDSTROM N . Concentrations of digoxin in plasma and urine in neonates, infants, and children with heart disease. Acta Paediatr Scand. 1974; 63(5):705-10. DOI: 10.1111/j.1651-2227.1974.tb16994.x. View

3.
Pruitt A, Dayton P, Patterson J . Disposition of diazoxide in children. Clin Pharmacol Ther. 1973; 14(1):73-82. DOI: 10.1002/cpt197314173. View

4.
Remmer H, Hirschmann J, Greiner I . [The significance of cumulation and elimination for the determination of Phenytoin (diphenylhydantoin)]. Dtsch Med Wochenschr. 1969; 94(24):1265-72. DOI: 10.1055/s-0028-1111205. View

5.
Krasula R, Pellegrino P, HASTREITER A, SOYKA L . Serum levels of digoxin in infants and children. J Pediatr. 1972; 81(3):566-9. DOI: 10.1016/s0022-3476(72)80193-8. View